儿童腹部神经母细胞瘤新辅助化疗后影像学定义危险因素的变化
回顾性分析43例接受新辅助化疗的腹部神经母细胞瘤患儿,初诊时共245个影像学定义危险因素(IDRF),化疗后显著降至156个(p < 0.001),多数IDRF(6/8,75.00%)显著改善(p < 0.05),但肾蒂及邻近结构受侵改善最不明显(p > 0.05);残留IDRF数量与术中出血量正相关(r = 0.399,p = 0.008),与术中并发症无相关(r = 0.111,p = 0.478)。
要点
- 新辅助化疗后IDRF总数显著减少(245降至156,p < 0.001),中位每例由6个降至4个。
- 肾蒂及邻近结构受侵是最不易改善的IDRF(p > 0.05)。
- 残留IDRF数量与术中出血量正相关(r = 0.399,p = 0.008)。
核心结论
- 不同类型神经母细胞瘤的IDRF在新辅助化疗后均可显著改善,但低及中等核分裂-核碎裂指数的神经母细胞瘤IDRF可能不易改善;残留IDRF数量可能与术中并发症发生无关。
研究设计与样本
- 回顾性研究,纳入2015年1月至2021年9月在本院接受新辅助化疗的腹部神经母细胞瘤患者43例,收集术中记录、组织病理学特征及初诊和新辅助化疗后的CT图像进行分析。
关键影像表现/征象
- 初诊时共发现245个IDRF,每例中位数6个[5, 7]。
- 新辅助化疗后IDRF显著减少至156个(p < 0.001),每例中位数剩余4个[3, 5]。
- 多数IDRF(6/8,75.00%)在新辅助化疗后显著改善(p < 0.05)。
- 肾蒂受侵(p > 0.05)和邻近结构受侵(p > 0.05)是最不易改善的IDRF。
诊断标准与关键数值
- IDRF总数初诊245个 vs 化疗后156个,化疗后显著减少(p < 0.001)。
- 每例IDRF中位数初诊6个[5, 7] vs 化疗后4个[3, 5]。
- 8类IDRF中6类(75.00%)显著改善(p < 0.05),肾蒂受侵(p > 0.05)和邻近结构受侵(p > 0.05)改善不显著。
- 残留IDRF数量与术中出血量正相关(r = 0.399,p = 0.008),与术中并发症无相关(r = 0.111,p = 0.478)。
临床应用与阅片要点
- 新辅助化疗后应重新评估IDRF,重点关注肾蒂及邻近结构受侵是否残留。
- 残留IDRF数量可能提示术中出血量增加,可在术前报告中予以描述。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: To observe the changes in image-defined risk factors (IDRFs) with neoadjuvant chemotherapy in pediatric abdominal neuroblastoma and to investigate the correlations between IDRF changes and histopathological features. In addition, this study also investigated the correlations between residual IDRFs after neoadjuvant chemotherapy and intraoperative complications.
METHODS: Forty-three patients with abdominal neuroblastoma who received neoadjuvant chemotherapy in our hospital from January 2015 to September 2021 were enrolled. Intraoperative records, histopathological features, and CT images at initial diagnosis and after neoadjuvant chemotherapy of all patients were retrospectively collected and analyzed.
RESULTS: A total of 245 IDRFs were found at initial diagnosis, with a median of 6 [5, 7] IDRFs per patient. After neoadjuvant chemotherapy, IDRFs significantly decreased to 156 (p < 0.001), with a median of 4 [3, 5] IDRFs remaining per patient. The majority of IDRFs (6/8, 75.00%) were significantly improved after neoadjuvant chemotherapy (p < 0.05), while tumor invasion of renal pedicles (p > 0.05) and adjacent structures (p > 0.05) was the least responsive IDRF. IDRFs in different types of neuroblastoma decreased significantly after neoadjuvant chemotherapy (p < 0.05), while they were not significant in neuroblastoma with low and intermediate mitosis-karyorrhexis indices (p > 0.05). The number of residual IDRFs correlated positively with the volumes of intraoperative blood loss (r = 0.399, p = 0.008), but not with the presence of intraoperative complications (r = 0.111, p = 0.478).
CONCLUSIONS: IDRFs in different types of neuroblastoma can be significantly improved after neoadjuvant chemotherapy, while IDRFs in neuroblastoma with low and intermediate mitosis-karyorrhexis indices might not be easily improved. At the same time, the number of residual IDRFs after neoadjuvant chemotherapy might not correlate with the occurrence of intraoperative complications in abdominal neuroblastoma.
引用
- Wang, Chen, Zhu, et al. Changes in image-defined risk factors with neoadjuvant chemotherapy in pediatric abdominal neuroblastoma. Abdom Radiol (NY). 2022. PMID: 35790567. doi:10.1007/s00261-022-03596-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。